Finance

Lists
Q3 2026 earnings • released • EPS beat +8.31% • Revenue beat +1.34%
See results
DXCM:NASDAQ
DexCom Inc
$84.76
+3.00%
(+2.47) 1D
$85.14
+0.45% (+0.38)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DXCM...
Open
$82.94
High
$85.20
Low
$82.52
Mkt. cap
31.61B
Avg. vol.
4.30M
Volume
0.00
P/E ratio
33.30
52-wk high
$92.59
52-wk low
$54.11
EPS
$2.55
Beta
1.48
Shares outstanding
372.95M
No. of employees
11K
Open
$82.94
High
$85.20
Low
$82.52
Mkt. cap
31.61B
Avg. vol.
4.30M
Volume
0.00
P/E ratio
33.30
52-wk high
$92.59
52-wk low
$54.11
EPS
$2.55
Beta
1.48
Shares outstanding
372.95M
No. of employees
11K
News stories
From web sources and news partners
Profile
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S., and manufacturing facilities in Mesa, Arizona, U.S.; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland. Wikipedia
About DexCom Inc
CEO-
Employees11K
Founded1999
HeadquartersSan Diego, California, United States
SectorMedical device
Websitedexcom.com
Analyst ratings
Based on 17 analysts giving stock ratings to DXCM in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for DXCM in the last 3 months.
Highest
Current $84.76
$120.00 (+41.58%)
Average
$99.56 (+17.46%)
Lowest
$85.00 (+0.28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Maintained
$94.00
+10.9%
11/02/2026
Robbie Marcus
J.P. Morgan
Hold
Reiterated
$85.00
+0.3%
10/30/2026
Jonathan Block
Stifel Nicolaus
Buy
Reiterated
$95.00
+12.1%
10/30/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$95.00
+12.1%
10/30/2026
Jayson Bedford
Raymond James
Buy
Maintained
$97.00
+14.4%
10/30/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$110.00
+29.8%
10/30/2026
Danielle Antalffy
UBS
Buy
Reiterated
$107.00
+26.2%
10/30/2026
Kendall Au
RBC Capital
Buy
Maintained
$105.00
+23.9%
10/29/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
$95.00
+12.1%
10/30/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
$97.00
+14.4%
10/30/2026
Christopher Pasquale
Barclays
Buy
Maintained
$120.00
+41.6%
10/30/2026
Patrick Wood
UBS
Buy
Maintained
$107.00
+26.2%
10/30/2026
Travis Steed
Bank of America Securities
Buy
Maintained
-
-
10/23/2026
Joanne Wuensch
Citi
Buy
Maintained
$105.00
+23.9%
10/21/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
$90.00
+6.2%
10/14/2026
Anthony Petrone
Mizuho Securities
Buy
Reiterated
$100.00
+18%
10/13/2026
Ryan Zimmerman
BTIG
Buy
Maintained
$96.00
+13.3%
10/12/2026
Marie Thibault
BTIG
Buy
Maintained
$96.00
+13.3%
10/12/2026
Matt Miksic
Barclays
Buy
Maintained
$115.00
+35.7%
10/07/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
$105.00
+23.9%
10/01/2026
Richard Newitter
Truist Financial
Buy
Maintained
$102.00
+20.3%
09/23/2026
Steven Silver
Argus Research
Buy
Maintained
$96.00
+13.3%
08/03/2026
Steven Lichtman
William Blair
Buy
Maintained
-
-
07/31/2026
Kieran Ryan
Deutsche Bank
Buy
Reiterated
$92.00
+8.5%
07/31/2026
Bruce Jackson
StoneX
Buy
Maintained
$82.00
-3.3%
07/31/2026
Jeff Johnson
Robert W. Baird
Buy
Maintained
$105.00
+23.9%
07/31/2026
Unknown Analyst
Deutsche Bank
Buy
Initiated
$86.00
+1.5%
06/25/2026
David Roman
Goldman Sachs
Buy
Maintained
$80.00
-5.6%
05/15/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
$85.00
+0.3%
05/15/2026
Lee Hambright
Bernstein
Buy
Maintained
$77.00
-9.2%
05/15/2026
Unknown Analyst
Jefferies
Buy
Maintained
$112.00
+32.1%
05/14/2026
Unknown Analyst
Argus Research
Buy
Maintained
$86.00
+1.5%
05/05/2026
Brandon Vazquez
William Blair
Buy
Maintained
$59.00
-30.4%
05/01/2026
Suraj Kalia
Oppenheimer
Hold
Reiterated
-
-
02/13/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
$0.73 / $0.67
+8.31%beat
Revenue / Est. (USD)
1.34B / 1.33B
+1.34%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.26B
1.19B
1.31B
1.34B
Cost of goods sold
466.90M
441.60M
478.40M
480.10M
Cost of revenue
466.90M
441.60M
478.40M
480.10M
Research and development expenses
148.20M
145.30M
153.00M
161.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
321.50M
349.70M
358.70M
375.60M
Operating expense
469.70M
495.00M
511.70M
537.20M
Total operating expenses
936.60M
936.60M
990.10M
1.02B
Operating income
323.00M
255.30M
318.30M
327.20M
Other non operating income
-1.60M
-2.20M
-4.70M
-3.70M
EBT including unusual items
340.70M
269.50M
317.50M
334.70M
EBT excluding unusual items
340.70M
269.50M
327.50M
334.70M
Income tax expense
73.40M
70.00M
68.40M
59.60M
Effective tax rate
21.54%
25.97%
21.54%
17.81%
Other operating expenses
-
-
-
-
Net income
267.30M
199.50M
249.10M
275.10M
Net profit margin
21.22%
16.74%
19.04%
20.46%
Earnings per share
0.68
0.56
0.70
0.73
Interest and investment income
23.50M
19.50M
16.90M
14.30M
Interest expense
-4.20M
-3.10M
-3.00M
-3.10M
Net interest expenses
19.30M
16.40M
13.90M
11.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
388.20M
322.40M
386.50M
401.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps